You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Baxter
Medtronic
Boehringer Ingelheim

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

NOVOLOG MIX 70/30 Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for NOVOLOG MIX 70/30

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Arecor LimitedPhase 1
The Cleveland ClinicPhase 4
Boston Medical CenterPhase 3

See all NOVOLOG MIX 70/30 clinical trials

Recent Litigation for NOVOLOG MIX 70/30

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-03
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-02

See all NOVOLOG MIX 70/30 litigation

Company Disclosures: US Patents for NOVOLOG MIX 70/30

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Basgsvaerd, DK) 2013-08-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2014-12-02 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 001 2002-05-03   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for NOVOLOG MIX 70/30

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132006901385693 Italy   Get Started for $10 PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005
40/2005 Austria   Get Started for $10 PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
CA 2005 00047 Denmark   Get Started for $10 PRODUCT NAME: INSULIN ASPART, PROTAMINKRYSTALLISERET
32/2000 Austria   Get Started for $10 PRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
SZ 50/1999 Austria   Get Started for $10 PRODUCT NAME: INSULIN ASPART
99C0044 Belgium   Get Started for $10 PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
SPC/GB99/045 United Kingdom   Get Started for $10 SPC/GB99/045: 20060829, EXPIRES: 20110828
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.